Replies to post #197119 on Biotech Values

[DewDiligence]

(BIIB)—CHMP approves Samsung Bioepis’ Imraldi (Humira FoB):

https://www.wsj.com/articles/samsung-makes-big-play-in-drug-market-with-cheaper-version-of-blockbuster-humira-1498217579

Imraldi will be marketed by BIIB in the EU, Switzerland, Russia, and Turkey (#msg-118427495). MRK holds the commercial rights in the US, where a 351(k) application has not yet been submitted, as far as I know.